CTNNB1 and neoplasm: Numerous predictive biomarkers have been associated with a better response to immune checkpoint inhibitors in other solid tumors including tumor mutational burden, PDL-1 protein expression [73–76], density of tumor infiltrating lymphocytes (TILs) [77], HLA class I diversity [78, 79], loss of heterogeneity at HLA class I alleles [80], T cell repertoire clonality change, T cell inflamed microenvironment, tumor-specific mutations, gut microbiome diversity, specific gut microbial species [81–83], TGF-beta expression [84], and mutations in beta-catenin pathway [85].